Clover had a write up in Brendan Lau's Small Caps column in last Thursday's AFR.
Main points:
- Some believe CLV is under-appreciated since it is on track to post 60% sales growth in the new financial year.
- CLV has delivered a 39% annual return compared to 11% for the ASX Small Industrial Index.
- CLV has tumbled 11% from Feb's five year high of 32c after its joint venture posted worse than expected losses.
- Healthy balance sheet with $30 million in cash and no debt.
- Microequities is forecasting a 30% lift in net profit to $4.2 million for 2009-10. - Next year's result could be even better if CLV sold some of its non-core assets.
- Carlos Gil from Microequities believes the outlook for CLV couldn't be brighter with exposure to the fast growing Omega-3 market in particular Asia.
CLV Price at posting:
28.5¢ Sentiment: Buy Disclosure: Held
